Head-to-head evidence
Lintuzumab-Ac225 vs PRGN-3006 T Cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
Lintuzumab-Ac225
Developed by Actinium Pharmaceuticals
NCT00006045 · Phase 3 · status unknown
This trial tested combination chemotherapy with or without an antibody therapy (lintuzumab) in patients with relapsed or refractory acute myeloid leukemia, but the public registry record does not state whether treatment assignment was randomized or blinded, and no outcome measures or results are available, so its design rigor and findings cannot be established from what is provided.
PRGN-3006 T Cells
Developed by Precigen, Inc
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lintuzumab-Ac225's landscape · PRGN-3006 T Cells's landscape